Jung Jin Oh et al. found no clinically significant pharmacodynamic or pharmacokinetic interactions between Aspirin and Fexuprazan, a recent randomized, open-label study in the “Pharmaceutics” journal described. A combination of Fexuprazan (potassium-competitive acid inhibitor) and Aspirin was thus found to be safe as it prevents gastrointestinal issues.

This study was performed to assess the drug pharmacodynamic/pharmacokinetic interactions between Aspirin and Fexuprazan when used together in healthy Korean individuals.

In the Aspirin group, the subjects were given Aspirin 500 mg plus Fexuprazan 80 mg. In the Fexuprazan group, Fexuprazan 80 mg was given alone and later along with Aspirin 500 mg. The platelet-to-platelet adhesion impeded by Aspirin and the pharmacokinetic interactions of Aspirin and this new potassium-competitive inhibitor were compared between single drug and combined drug use.

On the whole, 22 people completed the study. Fexuprazan coadministration did not considerably influence the platelet aggregation-inhibitory action and systemic exposure (pharmacodynamic effect) to Aspirin (also called Acetylsalicylic acid). The systemic exposure of Fexuprazan was lowered up to 20% when used with Aspirin, which was not of any clinical significance keeping in mind the earlier stated exposure–response relationship.

It is worth mentioning that no noteworthy drug-drug interactions between Aspirin and Fexuprazan were perceived in spite of the use of the dosage in the upper limit in the FDA guidelines. These findings offer persuasive evidence that Fexuprazan might serve as a viable option to prevent Aspirin-stimulated gastrointestinal complications, thereby indicating the clinical usefulness of its concomitant usage with Aspirin.